Polar Asset Management Partners Inc. Takes $7.80 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Polar Asset Management Partners Inc. acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 22,100 shares of the biotechnology company's stock, valued at approximately $7,798,000.

Other large investors have also recently modified their holdings of the company. Forum Financial Management LP increased its holdings in shares of United Therapeutics by 4.5% during the fourth quarter. Forum Financial Management LP now owns 1,313 shares of the biotechnology company's stock valued at $463,000 after acquiring an additional 57 shares in the last quarter. Formidable Asset Management LLC increased its stake in United Therapeutics by 34.5% during the 4th quarter. Formidable Asset Management LLC now owns 1,963 shares of the biotechnology company's stock worth $693,000 after buying an additional 504 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of United Therapeutics in the fourth quarter worth about $331,000. MidWestOne Financial Group Inc. boosted its stake in United Therapeutics by 23.2% during the fourth quarter. MidWestOne Financial Group Inc. now owns 6,847 shares of the biotechnology company's stock worth $2,416,000 after buying an additional 1,289 shares during the last quarter. Finally, CSS LLC IL grew its stake in shares of United Therapeutics by 13.7% in the 4th quarter. CSS LLC IL now owns 2,327 shares of the biotechnology company's stock valued at $821,000 after buying an additional 280 shares during the period. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. Morgan Stanley lifted their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a report on Monday, April 21st. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Trading Down 1.3%

Shares of United Therapeutics stock traded down $4.03 during mid-day trading on Friday, reaching $316.34. 886,326 shares of the stock were exchanged, compared to its average volume of 440,593. The firm has a 50-day simple moving average of $299.49 and a 200 day simple moving average of $334.86. United Therapeutics Co. has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The company has a market cap of $14.27 billion, a price-to-earnings ratio of 13.89, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter last year, the firm earned $6.17 EPS. The company's revenue for the quarter was up 17.2% on a year-over-year basis. On average, research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at $11,261,606.58. The trade was a 23.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,500 shares of company stock worth $16,923,950. Insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.